179 related articles for article (PubMed ID: 37470160)
1. Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugs.
Takamatsu H; Matsuda T; Mizuno S; Takahashi T; Fuchida SI; Hanamura I; Kataoka K; Tsukada N; Matsumoto M; Hangaishi A; Doki N; Uchida N; Sawa M; Maruyama Y; Kurahashi S; Nagafuji K; Harazaki Y; Kako S; Iida S; Ichinohe T; Kanda Y; Atsuta Y; Sunami K;
Haematologica; 2023 Dec; 108(12):3399-3408. PubMed ID: 37470160
[TBL] [Abstract][Full Text] [Related]
2. Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents.
Sahebi F; Iacobelli S; Sbianchi G; Koster L; Blaise D; Reményi P; Russell NH; Ljungman P; Kobbe G; Apperley J; Trneny M; Krejci M; Wiktor-Jedrzejczak W; Sanchez JF; Schaap N; Isaksson C; Lenhoff S; Browne P; Scheid C; Wilson KMO; Yakoub-Agha I; Muñiz SG; Schönland S; Morris C; Garderet L; Kröger N
Biol Blood Marrow Transplant; 2018 May; 24(5):930-936. PubMed ID: 29339268
[TBL] [Abstract][Full Text] [Related]
3. Second primary malignancies after autologous hematopoietic cell transplantation for multiple myeloma.
Krishnan AY; Mei M; Sun CL; Thomas SH; Teh JB; Kang T; Htut M; Somlo G; Sahebi F; Forman SJ; Bhatia S
Biol Blood Marrow Transplant; 2013 Feb; 19(2):260-5. PubMed ID: 23073267
[TBL] [Abstract][Full Text] [Related]
4. Secondary primary malignancies in patients with multiple myeloma: A single institution experience.
Fei F; Reddy V; Rosenblum F
Hematol Oncol; 2021 Dec; 39(5):674-679. PubMed ID: 34510500
[TBL] [Abstract][Full Text] [Related]
5. [Autologous stem cell transplantation improves outcomes of patients with multiple myeloma receiving proteasome inhibitors and lenalidomide treatment].
Ning X; Wei X; Guo X; Wei Q; Huang F; Fan Z; Xu N; Sun J; Feng R; Liu Q; Wei Y
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Aug; 41(9):1420-1425. PubMed ID: 34658359
[TBL] [Abstract][Full Text] [Related]
6. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
Yang FY; Wang HF; Xia LH; Wang QQ; Qian CJ; He J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620
[TBL] [Abstract][Full Text] [Related]
7. Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients.
Rosenberg AS; Brunson A; Tuscano J; Jonas BA; Hoeg R; Wun T; Keegan THM
Blood Cancer J; 2021 Jan; 11(1):5. PubMed ID: 33414400
[TBL] [Abstract][Full Text] [Related]
8. Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis.
Ragon BK; Shah MV; D'Souza A; Estrada-Merly N; Gowda L; George G; de Lima M; Hashmi S; Kharfan-Dabaja MA; Majhail NS; Banerjee R; Saad A; Hildebrandt GC; Mian H; Abid MB; Battiwalla M; Lekakis LJ; Patel SS; Murthy HS; Nieto Y; Strouse C; Badawy SM; Al Hadidi S; Dholaria B; Aljurf M; Vesole DH; Lee CH; Pawarode A; Gergis U; Miller KC; Holmberg LA; Afrough A; Solh M; Munshi PN; Nishihori T; Anderson LD; Wirk B; Kaur G; Qazilbash MH; Shah N; Kumar SK; Usmani SZ
Blood Adv; 2023 Jun; 7(12):2746-2757. PubMed ID: 36827681
[TBL] [Abstract][Full Text] [Related]
9. Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life.
Joseph NS; Gupta VA; Wyman S; Graiser M; Kaufman JL; Almaula D; Andrews J; Hofmeister C; Dhodapkar M; Heffner LT; Lonial S; Nooka AK
Transplant Cell Ther; 2022 Feb; 28(2):75.e1-75.e7. PubMed ID: 34626863
[TBL] [Abstract][Full Text] [Related]
10. Changing trends in prognostic factors for patients with multiple myeloma after autologous stem cell transplantation during the immunomodulator drug/proteasome inhibitor era.
Takamatsu H; Honda S; Miyamoto T; Yokoyama K; Hagiwara S; Ito T; Tomita N; Iida S; Iwasaki T; Sakamaki H; Suzuki R; Sunami K
Cancer Sci; 2015 Feb; 106(2):179-85. PubMed ID: 25530023
[TBL] [Abstract][Full Text] [Related]
11. Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis.
Saleem K; Franz J; Klem ML; Yabes JG; Boyiadzis M; Jones JR; Shaikh N; Lontos K
Lancet Haematol; 2022 Dec; 9(12):e906-e918. PubMed ID: 36354020
[TBL] [Abstract][Full Text] [Related]
12. Second primary malignancies in multiple myeloma: A review.
Poh C; Keegan T; Rosenberg AS
Blood Rev; 2021 Mar; 46():100757. PubMed ID: 32972803
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Autologous Stem Cell Transplantation for Myeloma Patients with Suboptimal Response: A Multicenter Retrospective Analysis.
Suzuki K; Shimazu Y; Minakata D; Ikeda T; Takahashi H; Tsukada N; Kanda Y; Doki N; Nishiwaki K; Miwa A; Sawa M; Kataoka K; Hiramoto N; Ota S; Itagaki M; Ichinohe T; Atsuta Y; Yano S; Kawamura K;
Transplant Cell Ther; 2023 Nov; 29(11):688.e1-688.e13. PubMed ID: 37574125
[TBL] [Abstract][Full Text] [Related]
14. Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019.
Swan D; Hayden PJ; Eikema DJ; Koster L; Sauer S; Blaise D; Nicholson E; Rabin N; Touzeau C; Byrne J; Huynh A; Cornelissen JJ; Potter V; Forcade E; Parrish C; Gribben J; Chretien ML; Mielke S; Gedde-Dahl T; Reményi P; Tsirigotis P; Garcia Guiñón A; Beksac M; Schönland S; Yakoub-Agha I
Br J Haematol; 2022 Apr; 197(1):82-96. PubMed ID: 35166376
[TBL] [Abstract][Full Text] [Related]
15. [Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].
Huang B; Li J; Liu J; Gu J; Zheng D; Xu D; Zou W; Wang H
Zhonghua Nei Ke Za Zhi; 2014 Nov; 53(11):865-72. PubMed ID: 25586356
[TBL] [Abstract][Full Text] [Related]
16. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.
Veltri LW; Milton DR; Delgado R; Shah N; Patel K; Nieto Y; Kebriaei P; Popat UR; Parmar S; Oran B; Ciurea S; Hosing C; Lee HC; Manasanch E; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH; Bashir Q
Cancer; 2017 Sep; 123(18):3568-3575. PubMed ID: 28513828
[TBL] [Abstract][Full Text] [Related]
17. Second stem cell transplantation for treatment of relapsed/refractory multiple myeloma after first autologous stem cell transplant: A 15-year retrospective institutional analysis.
Yadav N; Mirgh SP; Aggarwal M; Agrawal N; Mehta P; Khushoo V; Kapoor J; Bhatia N; Agrawal P; Ahmed R; Bhurani D
Indian J Cancer; 2023; 60(3):316-324. PubMed ID: 37787191
[TBL] [Abstract][Full Text] [Related]
18. Response and Dynamics of Renal Function in Transplantation-Eligible Multiple Myeloma Patients Treated with a Novel Agent: The CAREMM-2201 Study.
Kim Y; Park SS; Jeon YW; Yahng SA; Shin SH; Min CK;
Transplant Cell Ther; 2023 Jan; 29(1):55.e1-55.e9. PubMed ID: 36202336
[TBL] [Abstract][Full Text] [Related]
19. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
20. Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma.
Hashmi H; Atrash S; Jain J; Khasawneh G; Mohan M; Mahmoudjafari Z; Cui W; McGuirk J; Shune L; Ahmed N; Abdallah AO
Transplant Cell Ther; 2023 Apr; 29(4):262.e1-262.e6. PubMed ID: 36682468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
